Advertisement Oculus Confirms Effectiveness Of Microcyn At Inactivating H1N1 - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Oculus Confirms Effectiveness Of Microcyn At Inactivating H1N1

Reduced infectivity of swine flu virus by 4.00log10 (99.99%) after just 30-seconds of exposure

Oculus Innovative Sciences (Oculus) has confirmed the effectiveness of Microcyn Technology at inactivating the H1NI Swine Influenza A.

A virucidal time-kill suspension test conducted by BioScience Laboratories showed that the specific Microcyn technology formulation reduced infectivity of the swine flu virus by 4.00log10 (99.99%) reduction, after just 30-seconds of exposure. BioScience Laboratories, working in cooperation with the US Department of Agriculture, received formal approval to acquire, house and evaluate the specific swine influenza virus, in April 2009.

Oculus is preparing the study data for submission to both, the Centers for Disease Control and Prevention (CDC) and WHO, to help accelerate global awareness of Microcyn technology’s ability to effectively reduce the incidence of transmission of this pandemic virus.